Clinical Trials
임상시험 트래커
국내사는 전체 임상 이력, 글로벌 메이저는 진행 중 파이프라인을 추적합니다. ClinicalTrials.gov API v2에서 6시간 주기로 수집합니다.
기업
15 results
- 2상초청 등록· Philadelphia Chromosome Positive Acute Lymphoblastic LeukemiaAdding Asciminib to Usual Treatment for Adults With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia
협력: 노바티스
- 2상초청 등록· Acute Ischemic StrokeIntra-Arterial Tenecteplase Following Endovascular Thrombectomy for Large Vessel Occlusion Stroke
협력: 로슈
- 2상초청 등록· Breast Cancer MetastaticDetecting Tumor DNA in the Blood of HR+/HER2-low Metastatic Breast Cancer Patients to Find Candidates for T-DXd Therapy
협력: 아스트라제네카
- 2상초청 등록· Chronic Rhinosinusitis With Nasal PolypsLong-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Clinical Study
리드: 사노피
- 2상초청 등록· Myotonic Dystrophy Type 1 (DM1)A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type I
리드: 버텍스
- 2상초청 등록· Age Related Macular Degeneration (AMD)ORACLE: A Long-term Follow-up Study to Evaluate the Safety of GT005 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration Treated in a Gyroscope-sponsored Antecedent Study
협력: 노바티스
- 2상초청 등록· Diabetic Retinopathy, DRLong-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With and Without Diabetic Retinopathy
리드: 애브비
- 2상초청 등록· Neovascular Age-Related Macular Degeneration (nAMD)Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMD
리드: 애브비
- 2상초청 등록· Multiple MyelomaA Nationwide Phase 2 Trial of Patients With Smoldering and Active Multiple Myeloma (MM)
협력: 암젠
- 2상초청 등록· Neovascular Age-related Macular DegenerationLong-term Follow-Up Study of RGX-314 and Fellow Eye Substudy
리드: 애브비
- 2상초청 등록· Heart TransplantationThe Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients
협력: 사노피
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.